42nd week of 2011 patent applcation highlights part 46 |
Patent application number | Title | Published |
20110257039 | REVERSE TRANSCRIPTION PRIMERS AND METHODS OF DESIGN - The present invention provides novel algorithms for designing oligonucleotides that do not substantially hybridize to a small group of unwanted transcripts, while hybridizing to most other transcripts. Such oligonucleotides are particularly useful as primers for reverse transcription. The invention also provides compositions containing oligonucleotides that do not substantially hybridize to a small group of unwanted transcripts, while hybridizing to most other transcripts. | 2011-10-20 |
20110257040 | NANOSCALE APERTURES HAVING ISLANDS OF FUNCTIONALITY - Methods, compositions and arrays for non-random loading of single analyte molecules into array structures are provided. Arrays of confined regions are produced wherein each confined region comprises a single island within the confined region. The island can be selectively functionalized with a coupling agent to couple a single molecule of interest within the confined region. | 2011-10-20 |
20110257041 | BIO-FIELD PROGRAMMABLE GATE ARRAY AND BIO-PROGRAMMABLE LOGIC ARRAY: RECONFIGURABLE CHASSIS CONSTRUCTION - Aspects of the invention relate to reconfigurable chassis that allow for rapid construction and optimization of biocircuits. | 2011-10-20 |
20110257042 | Debulking Catheters And Methods - A debulking catheter comprising a tissue debulking assembly for removing a continuous strand of material from a body lumen. Catheters of the present invention generally include a catheter body having proximal and distal portions and a tissue debulking assembly disposed at least partially within the distal portion. The tissue debulking assembly is radially movable to expose at least a portion of the assembly through a window on the catheter body. The catheter is advanced transluminally through the body lumen to contact material in the body lumen and remove a plane of continuous material that has a length that is typically longer than a length of the window on the catheter. The continuous material may be directed into a collection chamber. Thereafter, the material may be removed from the collection chamber and preserved or tested. | 2011-10-20 |
20110257043 | ULTRA HIGH-THROUGHPUT OPTI-NANOPORE DNA READOUT PLATFORM - Described herein are methods for analyzing polymer molecules. These methods are employed for the high throughput readout of DNA and RNA molecules with single molecule sensitivity. The method of the present invention comprises (1) the electrically controlled unzipping of DNA (or RNA) double strands, and (2) the readout of the molecule's identity (or code) using one or more molecule signal detection. | 2011-10-20 |
20110257044 | Structure-based construction of human antibody library - Methods and systems are provided for constructing recombinant antibody libraries based on three-dimensional structures of antibodies from various species including human. In one aspect, a library of antibodies with diverse sequences is efficiently constructed in silico to represent the structural repertoire of the vertebrate antibodies. Such a functionally representative library provides a structurally diverse and yet functionally more relevant source of antibody candidates which can then be screened for high affinity binding to a wide variety of target molecules, including but not limited to biomacromolecules such as protein, peptide, and nucleic acids, and small molecules. | 2011-10-20 |
20110257045 | METHOD FOR PREPARING HIGH-THROUGHPUT SEQUENCEABLE DNA FROM INDIVIDUAL PLAQUES OF PHAGES PRESENTING PEPTIDES - The present invention relates to a process for isolating DNA from individual plaques of peptide-presenting bacteriophages in a high-throughput capacity PCR, wherein the PCR products obtained are sequenceable and a specimen of each phage studied is retained in a replicable state. The PCR is successful despite the presence of inhibitory constituents from the growth medium or the host bacteria. | 2011-10-20 |
20110257046 | Emulsion PCR And Amplicon Capture - Compositions and methods of use are disclosed for clonally amplifying target polynucleotide sequences in solution and attaching the amplicons to a surface by activation of a masked binding moiety. | 2011-10-20 |
20110257047 | Methods for Labeling a Substrate Using a Hetero-Diels-Alder Reaction - Methods for labeling a substrate using a hetero-Diels-Alder reaction are disclosed. The hetero-Diels-Alder reaction includes the reaction of an o-quinone methide (e.g., an o-naphthoquinone methide) with a polarized olefin to form a hetero-Diels-Alder adduct. The o-quinone methide or the polarized olefin can be attached to a surface of a substrate, and the other of the o-quinone methide or the polarized olefin can include a detectable label. The o-quinone methide can conveniently be generated by irradiation of a precursor compound, preferably in an aqueous solution, suspension, or dispersion. | 2011-10-20 |
20110257048 | Reactor Array for Producing and Analyzing Products - The present invention relates to a reactor array for producing and/or analysing products, comprising a plurality of vessels in which products can be produced on a preparative or analytical scale. | 2011-10-20 |
20110257049 | Sample Block Apparatus and Method for Maintaining a Microcard on a Sample Block - A thermal cycling device for thermally cycling samples of biological material contained in a microcard having a top and bottom surface. The thermal cycling device can include a sample block having an upper surface configured for engaging the bottom surface of a microcard, a vacuum device, and a temperature control system operatively connected with the sample block. The upper surface of the sample block may include a plurality of channels, the channels defining spaces between the sample block and the bottom surface of a microcard that may be positioned thereon. The vacuum device may be in fluid communication with the sample block for drawing gas out of the spaces defined by the channels in the sample block. The vacuum device may be configured for substantially maintaining a vacuum between the sample block and microcard so that a retention force is imparted on the microcard to urge the microcard toward the sample block. Methods of maintaining a microcard on a sample block of a thermal cycling device are also provided. | 2011-10-20 |
20110257050 | DRY BLEND FRACTURING FLUID ADDITIVES - A method and composition for crosslinking a polymer based fluid includes providing a dry blend of crosslinker and delay agent. The crosslinker and delay agent are mixed and granulated in a dry form prior to addition to the polymer fluid. | 2011-10-20 |
20110257051 | Consolidating Emulsions Comprising Convertible Surfactant Compositions and Methods Related Thereto - Methods are provided that include a method comprising: providing an emulsified treatment fluid comprising an oleaginous phase, an aqueous phase, a consolidating agent, and an emulsifying agent that comprises at least one convertible surfactant described by a one of the disclosed formulae, and placing the subterranean treatment fluid in a subterranean formation. | 2011-10-20 |
20110257052 | Method for Practicing Microbial Enhanced Oil Recovery Using Nitrogen Containing Fertilizers Recovered from Contaminated Water for Feeding Microbes - A method of using nitrates, nitrites, or ammonium recovered from contaminated water for feeding microbes used in microbial enhanced oil recovery (MEOR). If required, the nitrogen waste removed from contaminated waters is treated to be converted as nitrates or nitrites. The nitrates and nitrites are mixed with microbes that are then injected into oil wells for improved tertiary oil production or injected separately depending on balance of feed and microbes in well brine as judged from examining brine that exits well with the oil. The use of nitrates recovered from contaminated waters to feed microbes in MEOR is cost effective for both the process of water decontamination and oil recovery. | 2011-10-20 |
20110257053 | LUBRICATION KIT AND SMALL ELECTRONIC DEVICE USING THE SAME - [Object] To provide a lubrication kit which is capable of improving wear resistance and durability of a sliding portion mounted in a small electronic device and which is capable of reducing a sound generated during driving. | 2011-10-20 |
20110257054 | Lubricant Composition and Method of Forming - The present disclosure describes compositions and a method for forming such compositions. More specifically, inorganic microparticles and surface modified silica nanoparticles are mixed to form a composition. The surface modified silica nanoparticles are present in the composition in an amount sufficient to decrease the coefficient of friction relative to a comparable composition that is free of surface modified silica nanoparticles. | 2011-10-20 |
20110257055 | Composite Particles and Method of Forming - Composite particles and a method of forming composite particles are described. The composite particles comprise at least one inorganic nanoparticle covalently bound to at least one inorganic microparticle with a linking compound. Lubricant compositions and sprayable dispersion compositions comprising composite particles are also described. | 2011-10-20 |
20110257056 | SOLUTION FOR REMOVING TITANIUM-CONTAINING COATINGS AND REMOVING METHOD USING SAME - A solution for removing titanium-containing coatings from substrates is provided. The solution includes hydrogen peroxide and fluoride. The hydrogen peroxide is in a concentration of about 100-800 ml/L. The fluoride is in a concentration of about 1-50 g/L. A method for removing titanium-containing coating from a substrate is also described there. | 2011-10-20 |
20110257057 | CLEANING SOLUTION FOR STAINLESS STEEL AND CLEANING METHOD USING SAME - A cleaning solution for cleaning stainless steels etched by ferric or ferrous salt solution is provided. The cleaning solution including: one or more ingredients selected from a group consisting of inorganic acid, inorganic alkali metal salt, and inorganic alkaline-earth metal salt in a concentration of about 200-600 g/L; complexant being capable of complexing with ferric or ferrous ions in a concentration of about 26-275 g/L; and one of carboxylic acid and carboxylate, or a combination thereof, in a concentration of about 75-250 g/L. A method for cleaning the stainless steels is also described there. | 2011-10-20 |
20110257058 | Detergent Composition - Detergent composition in free flowing particulate form, wherein the detergent composition has free flowing secondary particles having a particle size of from 200 μm to 1500 μm and has primary particles which have a particle size of from 2 μm to 50 μm and which have at least 80% by weight of insoluble polymeric material. | 2011-10-20 |
20110257059 | Process for Making a Detergent - A process for the production of a spray-dried detergent powder including a hexagonal-phase-in-water-forming surfactant the process including the steps of: (i) spraying into a spray-drying tower a detergent slurry preferably free of a hexagonal-phase-in-water-forming surfactant; and (ii) simultaneously spraying a paste having a hexagonal-phase-in-water-forming surfactant, whereby droplets of the slurry encounter droplets or powder of the hexagonal-phase-in-water-forming surfactant paste so as to form composite granules. | 2011-10-20 |
20110257060 | LAUNDRY DETERGENT COMPOSITION COMPRISING BLEACH PARTICLES THAT ARE SUSPENDED WITHIN A CONTINUOUS LIQUID PHASE - A non-unit dose laundry detergent composition suitable for use in a single-compartment container including: (a) detersive surfactant; (b) from 0 wt % to 10 wt % water; (c) bleach; (d) optionally, from 0 wt % to 5 wt % citric acid; and (e) optionally, from 0 wt % to 5 wt % fatty acid, wherein the composition comprises at least 1 wt % solid particles suspended within a continuous liquid phase, wherein the suspended solid particles comprise bleach, wherein the weight average particle size of the suspended solid bleach particles is at least 1 micrometer, wherein at least 95 wt % of the suspended solid bleach particle sizes have a size in the range of from 0.1 micrometers to 500 micrometers, wherein the density of the suspended solid bleach particles is less than 500 g/l, and wherein the dynamic viscosity of the continuous liquid phase is in the range of from 100 mPas to 500 mPas. | 2011-10-20 |
20110257061 | Solid Detrgent Composition Comprising Beta Cyclodextrin - A solid detergent composition including: (a) detersive surfactant; (b) beta cyclodextrin; (c) essentially free from zeolite builder; (d) essentially free from phosphate builder; (e) optionally, essentially free from silicate; and (f) optionally perfume; and (g) optionally, additional detergent ingredients. | 2011-10-20 |
20110257062 | LIQUID LAUNDRY DETERGENT COMPOSITION COMPRISING A SOURCE OF PERACID AND HAVING A PH PROFILE THAT IS CONTROLLED WITH RESPECT TO THE PKA OF THE SOURCE OF PERACID - The present invention relates to a non-unit dose liquid laundry detergent composition suitable for use in a single-compartment container comprising:
| 2011-10-20 |
20110257063 | Mildly Alkaline, Low-Built, Solid Fabric Treatment Detergent Composition Comprising Perhydrolase - A solid fabric treatment detergent composition including: (i) detersive surfactant; (ii) perhydrolase; (iii) substrate for perhydrolase; (iv) source of hydrogen peroxide; (v) from 0 wt % to 10 wt % zeolite builder; (vi) from 0 wt % to 10 w % phosphate builder; and (vii) optionally, from 0 wt % to 10 wt % silicate salt, wherein the upon dilution in de-ionized water to a concentration of 1 wt % at 20° C., the composition has a pH in the range of from 7.6 to 8.8. | 2011-10-20 |
20110257064 | Solid Laundry Detergent Composition Having a Dynamic In-Wash PH Profile - A free-flowing solid laundry detergent composition including: (a) detersive surfactant; (b) essentially free from zeolite builder; (c) essentially free from phosphate builder; and (d) optionally, essentially free from silicate salt; wherein the composition has a reserve alkalinity to pH 7.5 of less than 15, and wherein upon dilution in de-ionised water to form a wash liquor at 10° C. temperature and at 1 g/L concentration has a pH profile such that: (i) 3 minutes after contact with water, the pH of the wash liquor is greater than 10; (ii) 10 mins after contact with water, the pH of the wash liquor is less than 9.5; (iii) 20 mins after contact with water, the pH of the wash liquor is less than 9.0; and (iv) optionally, wherein, the equilibrium pH of the wash liquor is in the range of from above 7.0 to 8.5. | 2011-10-20 |
20110257065 | Detergent Composition - Laundry detergent composition having:
| 2011-10-20 |
20110257066 | Detergent Composition - Preparation of solid free flowing detergent composition by spray drying a chemically simple slurry as well as compositions comprising chemically simple spray dried particles | 2011-10-20 |
20110257067 | Process for Making a Detergent - A process for making a detergent composition including the step of forming a low-water-containing surfactant mixture including: i) a hexagonal-phase-in-water-forming surfactant; and ii) a sulphonate detersive surfactant. | 2011-10-20 |
20110257068 | ULTRASONIC TREATMENT CHAMBER FOR PREPARING EMULSIONS - An ultrasonic mixing system having a treatment chamber in which at least two separate phases can be mixed to prepare an emulsion is disclosed. Specifically, at least one phase is a dispersed phase and one phase in a continuous phase. The treatment chamber has an elongate housing through which the phases flow longitudinally from a first inlet port and a second inlet port, respectively, to an outlet port thereof. An elongate ultrasonic waveguide assembly extends within the housing and is operable at a predetermined ultrasonic frequency to ultrasonically energize the phases within the housing. An elongate ultrasonic horn of the waveguide assembly is disposed at least in part intermediate the inlet and outlet ports, and has a plurality of discrete agitating members in contact with and extending transversely outward from the horn intermediate the inlet and outlet ports in longitudinally spaced relationship with each other. The horn and agitating members are constructed and arranged for dynamic motion of the agitating members relative to the horn at the predetermined frequency and to operate in an ultrasonic cavitation mode of the agitating members corresponding to the predetermined frequency and the phases being mixed in the chamber. | 2011-10-20 |
20110257069 | DETERGENT COMPOSITION - Colloidal detergent composition having a continuous liquid phase and a discontinuous solid phase having suspended solid particles, the detergent composition having less than 15 wt % of water, the total ionic strength of the colloidal detergent composition which is present in the liquid phase (TISl/c) being of less than 4300 mmol/kg, the total ionic strength of the colloidal detergent composition which is present in the solid phase (TISs/c) being of more than 100 mmol/kg, the ratio TISs/c/TISl/c being above 0.025. | 2011-10-20 |
20110257070 | LIQUID DETERGENT COMPOSITION COMPRISING AN EXTERNAL STRUCTURING SYSTEM COMPRISING A BACTERIAL CELLULOSE NETWORK - A structured liquid detergent composition in the form of a liquid matrix made up of an external structuring system of a bacterial cellulose network; water; and surfactant system including an anionic surfactant; a nonionic surfactant; a cationic surfactant; an ampholytic surfactant; a zwitterionic surfactant; or mixtures thereof, wherein said liquid matrix has a yield stress of from about 0.003 Pa to about 5.0 Pa at about 25° C. and provides suitable particle suspension capabilities and shear thinning characteristics. | 2011-10-20 |
20110257071 | FERRIC HYDROXYCARBOXYLATE AS A BUILDER - The use of ferric hydroxycarboxylate as a chelator and builder for cleaning compositions is disclosed. The cleaning composition may be formulated for warewashing, laundering, and for other means of removing soils and includes a ferric hydroxycarboxylate, an alkalinity source and a surfactant system. The cleaning composition has a pH of between about 9 and about 12. | 2011-10-20 |
20110257072 | NOVEL ACYLALKYLISETHIONATE ESTERS AND APPLICATIONS IN CONSUMER PRODUCTS - Acylalkylisethionate esters are produced by reacting one or more carboxylic acids with one or more alkyl-substituted hydroxyalkyl sulfonates under esterification reaction conditions. The alkyl-substituted hydroxyalkyl sulfonates used as a raw material in producing the esters are prepared by reacting bisulfate with one or more alkylene oxides. The acylalkylisethionate esters may be used in consumer products. | 2011-10-20 |
20110257073 | METHODS OF MAKING FLUORINATED ETHERS, FLUORINATED ETHERS, AND USES THEREOF - A method of making a fluorinated ether includes combining, in a polar aprotic solvent: a fluorinated alcohol represented by the formula X—R | 2011-10-20 |
20110257074 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION - Methods of purifying individual congeners of substituted cyclohexa-2,4-dienones, substituted cyclohexane-1,3,5-triones, substituted cyclopent-2-en-1-ones, and substituted 1,3-cyclopentadiones and compositions using the same are disclosed. The purification method includes the steps of: (a) selecting a congener to be isolated; (b) dissolving the mixture of congeners in a bi-phasic solvent system specific to the selected congener to be isolated, wherein said bi-phasic system has a partition coefficient from about 0.5 to 5.0; (c) subjecting the mixture dissolved in the bi-phasic solvent system to a counter current chromatography; and (d) isolating the selected congener in substantially pure form. | 2011-10-20 |
20110257075 | GUANIDINO ACETIC ACID USED AS AN ANIMAL FOOD ADDITIVE - The present invention relates to the use of guanidinoacetic acid and/or salts thereof as feed additive, in predominantly vegetarian diets, in particular use being made of salts with hydrochloric acid, hydrobromic acid and phosphoric acid. The use proceeds especially in individual doses from 0.01 to 100 g/kg of feed in the form of powders, granules, pastilles or capsules, the feed additive also being able to be used in combination with other physiologically active materials of value. The claimed use which is suitable especially for breeding and growing livestock, has recourse to a compound which is in particular stable in aqueous solution, can be converted to creatine under physiological conditions, and, in contrast to other guanidine derivatives, is completely available to physiological sectors of use. | 2011-10-20 |
20110257076 | AMIDE BASED INSULIN PRODRUGS - Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half lives of at least 10 hours, and more typically greater than 2 hours, 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 2011-10-20 |
20110257077 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS - The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase. | 2011-10-20 |
20110257078 | ANTIBACTERIAL COMBINATION THERAPY FOR THE TREATMENT OF GRAM POSITIVE BACTERIAL INFECTIONS - There is described a composition comprising a therapeutically active imidazole, and derivatives thereof, and an agent active on a bacterial cell surface selected from the group consisting of one or more of colistin, nisin, D-cycloserine, fosfomycin, fosfomycin trometamol, fosfomycin disodium and polymixin B, and derivatives thereof. | 2011-10-20 |
20110257079 | Parenteral Combination Therapy for Infective Conditions With Drug Resistant Bacterium - The invention describes a pharmaceutical composition to combat multiple-drug-resistant bacteria in non-ocular infective conditions. Compositions comprising glycopeptides, in particular vancomycin, and cephalosporins, in particular ceftriaxone, are disclosed. Such compositions are found to be useful for parenteral administration for hospitalized patients with serious infections. Specifically, this invention also discloses a pharmaceutical composition further including an excipient such as CVMC agent and is available in dry powder form for reconstitution before injection with a suitable solvent. The pharmaceutical compositions of this invention have been found normally to enhance resistance to precipitation in solutions to be administered parenterally. The invention also gives details of the dosage forms stored in sealed containers to be reconstituted before use. The invention further provides a process to manufacture these compositions and also a method of treating a subject having non-ocular infective conditions due to multi drug resistant bacterium. | 2011-10-20 |
20110257080 | Hepatitis B Virus Compositions and Methods of Use - A polypeptide comprising a preS1 region of hepatitis B virus (HBV), or a fragment thereof, and/or the preS2 region of HBV or a fragment thereof, and methods of use to inhibit virus infection are disclosed. A lentivirus comprising hepatitis B virus (HBV) envelope proteins, or a fragment thereof, and/or the L envelope protein of HBV and/or the M envelope protein of HBV or a fragment thereof, and/or the S envelope protein of HBV or a fragment thereof, and methods of use of this lentivirus HBV pseudovirus as a gene therapy to target hepatocytes for the administration of therapeutic agents are also disclosed. | 2011-10-20 |
20110257081 | MULTIGAND CONSTRUCTS - Multiligand constructs and intermediate multivalent constructs for use in their preparation are described. The multiligand constructs have utility in diagnostic and therapeutic applications. | 2011-10-20 |
20110257082 | HIV-1 INTEGRASE DERIVED STIMULATORY PEPTIDES INTERFERING WITH INTEGRASE -- REV PROTEIN BINDING - Isolated peptides comprising sequences derived from the protein integrase of HIV-1, as well as their analogs, mixtures, conjugates with permeability enhancing moieties, and pharmaceutical compositions are disclosed. The peptides and compositions are capable of selectively killing HIV-1 infected cells and are used in treatment of HIV infection and AIDS. | 2011-10-20 |
20110257083 | MSP-1 PROTEIN PREPARATIONS FROM PLASMODIUM - The invention relates to a merozoite surface protein 1 (“MSP-1”) preparation | 2011-10-20 |
20110257084 | EXENDIN DERIVATIVE LINKED BIOTIN, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are exendin-3 or exendin-4 derivatives modified with biotin, a preparation method thereof and a pharmaceutical composition containing the same. More specifically, disclosed are exendin-3 or exendin-4 derivatives in which the lysine residue of exedin is modified with biotin. The disclosed exendin-3 or exendin-4 derivatives modified with biotin show biological activity similar to that of native exendin and at the same time, have increased in vivo stability and are easily absorbed through the mucosa. Thus, biotin-modified exendin-3 or exendin-4 derivatives are useful for treating diseases, which can be caused by the excessive secretion of insulin, the lowering of plasma glucose, the inhibition of gastric or intestinal motility, the inhibition of gastric or intestinal emptying or the inhibition of food intake. Particularly, the biotin-modified exendin-3 or exendin-4 derivatives are useful for the treatment of diabetes, obesity and irritable bowel syndromes. | 2011-10-20 |
20110257085 | Crystal Forms of Saxagliptin and Processes for Preparing Same - Physical crystal structures of a compound of the formula I: | 2011-10-20 |
20110257086 | METHODS FOR SYNTHESIS AND USES OF INHIBITORS OF GHRELIN O-ACYLTRANSFERASE AS POTENTIAL THERAPEUTIC AGENTS FOR OBESITY AND DIABETES - The invention provides inhibitors of ghrelin O-acyltransferase, and methods of making and using them. In some embodiments, the invention provides bisubstrate analog inhibitors of ghrelin O-acyltransferase, which can be effective in treating, for example, obesity and diabetes mellitus. | 2011-10-20 |
20110257087 | Protein Hydrolysate Compositions Having Enhanced CCK Releasing Activity - The present invention provides protein hydrolysate compositions having enhanced cholecystokinin (CCK) releasing activity that can be used to promote satiety. | 2011-10-20 |
20110257088 | Low-Concentration Nutritional Composition - The present invention provides an enteral nutritional composition with which the labor of administering water between meals can be saved. The enthral nutritional composition comprises proteins, carbohydrates and lipids, with the calories per ml of the composition being less than 1 kcal and the moisture content being 30 percent by mass or more. | 2011-10-20 |
20110257089 | LIQUID HIGH-FAT PROTEIN COMPOSITION - The invention concerns nutritional compositions for persons with a (partially) functional gastrointestinal tract, who are unwilling and/or unable to consume sufficient quantities of conventional food to meet their nutritional requirements such as malnourished persons or persons at risk of becoming malnourished, and in need of liquid oral nutrition. The shelf-stable liquid nutritional compositions comprise at least non-micellar casein, a high amount of fat, and optionally a heat stabilisation system. | 2011-10-20 |
20110257090 | SOLUTIONS FOR VOLUME THERAPY - The invention relates to artificial plasma-like solutions and methods for their use. The subject solutions find use in a variety of applications, particularly in those applications where at least a portion of a host's blood volume is replaced with a blood substitute. | 2011-10-20 |
20110257091 | INSULIN ANALOGS - Full potency analogs of insulin are provided wherein the analog comprises a modification of the tyrosine residue at position 19 of the A chain. | 2011-10-20 |
20110257092 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR). | 2011-10-20 |
20110257093 | THERAPIES FOR ACUTE RENAL FAILURE - The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-β superfamily of proteins. | 2011-10-20 |
20110257094 | ANTI PERIODONTITIS-CAUSING MICROORGANISM AGENT AND MEDICAL OR DENTAL MATERIALS USING THE SAME - A medical or dental material can be prepared by using, as an active ingredient, at least one of a protamine, and derivatives thereof and hydrolysates thereof, or a complex of at least one of a protamine, and derivatives thereof and hydrolysates thereof with an anionic high molecular weight compound. As a result, an antibacterial agent against periodontal disease-causing bacteria can be provided, which is highly safe without concern of a side effect. A medical or dental material can be also provided, which exhibits antimicrobial activity on periodontal disease-causing bacteria and additionally has insolubility in water and good formability. | 2011-10-20 |
20110257095 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY - The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. | 2011-10-20 |
20110257096 | COMPOSITIONS FOR DRUG ADMINISTRATION - The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery of peptides containing non-naturally occurring structures including D-amino acids and/or chain cyclization. | 2011-10-20 |
20110257097 | PHARMACEUTICAL COMPOSITIONS OF SOMATOTROPHIC HORMONES - The invention provides a composition comprising (i) a somatotrophic hormone; (ii) a biodegradable polymer component; and (iii) a release modifier. A process for preparing, and the use of such a composition are also provided. | 2011-10-20 |
20110257098 | COMPOSITIONS AND METHODS FOR TREATING GROWTH HORMONE DEFICIENCY - The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping. | 2011-10-20 |
20110257099 | Use of Natriuretic Peptide for Treating Heart Failure - The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours. | 2011-10-20 |
20110257100 | Inhibitors of Protein Tyrosine Kinase Activity - This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions. | 2011-10-20 |
20110257101 | CATECHOLAMINE REGULATED PROTEIN - A novel mammalian catecholamine-regulated protein called CRP40 is identified. This protein, and nucleic acid encoding same, is useful in methods of diagnosing and treating hypodopaminergic neurological disease, such as Parkinson's disease, multisystem atrophy, lewy body dementia, schizophrenia, and bipolar disease. | 2011-10-20 |
20110257102 | COMPOSITIONS AND METHODS OF TREATING CANCER - A method of inhibiting neoplastic, cancer, and/or tumorgenic cell proliferation, cell growth and motility in a subject includes administering to a cancer cell expressing Pro-PrP and FLNa a therapeutically effective amount of a Pro-PrP regulating agent. | 2011-10-20 |
20110257103 | Compositions and methods for the treatment of sj?rgren's syndrome - This invention provides a method of inducing a lacrimal acinar cell in a tissue to degrade a secretory vesicle and its content protein or proteins from the trans-Golgi network (TGN) by contacting the cells with an effective amount of an agent that induces autophagy. Also provided is a method for treating a mammal suffering from defective trans-Golgi network-secretory vesicle (TGN-SV) sorting by administering to the mammal an effective amount of an agent that induces autophagy in the tissue having the defective TGN-SV. | 2011-10-20 |
20110257104 | METHODS TO IDENTIFY MACROMOLECULE BINDING AND AGGREGATION PRONE REGIONS IN PROTEINS AND USES THEREFOR - The present invention provides methods and computational tools based, at least in part, on computer simulations that identify macromolecule binding regions and aggregation prone regions of a protein. Substitutions may then be made in these aggregation prone regions to engineer proteins with enhanced stability and/or a reduced propensity for aggregation. Similarly, substitutions may then be made in these macromolecule binding regions to engineer proteins with altered binding affinity for the macromolecule. | 2011-10-20 |
20110257105 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF - The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P | 2011-10-20 |
20110257106 | Polymer Stabilized Neuropeptides - A substantially hydrophilic conjugate is provided having a peptide that is capable of passing the blood-brain barrier covalently linked to a water-soluble nonpeptidic polymer such as polyethylene glycol. The conjugate exhibits improved solubility and in vivo stability and is capable of passing the blood-brain barrier of an animal. | 2011-10-20 |
20110257107 | Compounds for Delivering Amino Acids or Peptides with Antioxidant Activity into Mitochondria - Disclosed are compounds containing single amino acids, peptides, or derivatives thereof which are selectively delivered to the mitochondria of a cell. Compounds of the invention exhibit antioxidant activity thereby reducing reactive oxygen species in cells. These compounds are useful for inhibiting oxidative stress-induced cell injury or death both in vivo and ex vivo. In addition, methods for the synthesis of these compounds are disclosed. | 2011-10-20 |
20110257108 | SYNTHESIS AND ACTIVITY OF LACTOSE ESTERS - This disclosure provides for a novel lactose monolaurate (LML) with the structure | 2011-10-20 |
20110257109 | USE OF DRUGS THAT ACTIVATE P2Y RECEPTORS TO ENHANCE SYNAPTOGENESIS - The present invention encompasses compositions and methods that activate P2Y receptors for the increased production of new synapses in the central nervous system. The formulations of the invention may be administered to a healthy subject or to a subject in need thereof to restore synapses. | 2011-10-20 |
20110257110 | Composition comprising a glycoside of a mono- or diacylglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, a method of producing the composition and use of the composition - A composition and use of a composition comprising a glycoside of a mono- or diacylglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, e.g. fish oil. The composition may also comprise a rose hip concentrate. The composition is used to treat inflammatory diseases, e.g. joint diseases such as osteoarthritis, or joint pain and stiffness. By administering the composition on a daily basis, a significant reduction in joint pain and stiffness of the affected joints is achieved, which allows individuals suffering from especially joint diseases to resume daily activities. | 2011-10-20 |
20110257111 | Hydroxyethlamino Sulfonamide Derivatives - This invention relates to novel hydroxyethylamino sulfonamides and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act as an HIV (human immunodeficiency virus) protease inhibitor. | 2011-10-20 |
20110257112 | ISOLATED COMPOUNDS FROM PHALERIA MACROCARPA AS ANTI-CANCER AGENTS - The invention concerns compounds DLBS1425E2.2 and DLBS1425F1 isolated and identified from the extract of the plant | 2011-10-20 |
20110257113 | Method for Inducing a Trif-Bias - The use of a selected aminoalkyl glusoaminide 4-phosphate (AGP) CRX-547 to induce a TRIF biased response in a human system, which results in reduced levels of MyD88-dependent cytokines relative to the MyD88-dependent cytokines induced by its diastereomer AGP CRX-527. | 2011-10-20 |
20110257114 | CRYSTALLINE FORMS OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL] HEXANE - The novel crystalline and polymorphic forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-α-D-mannopyranosyloxy)-phenyl]hexane have advantageous properties and can be used in pharmaceutical and dermatological compositions. | 2011-10-20 |
20110257115 | METHOD FOR TREATING RHINITIS AND SINUSITIS BY RHAMNOLIPIDS - The present invention is directed to methods for treating rhinitis or sinusitis in a subject. In one embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a formulation comprising an only active ingredient of an effective amount of rhamnolipid. In another embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a first active ingredient of an effective amount of a rhamnolipid and a second active ingredient of an effective amount of a corticosteroid, an antihistamine, a leukotriene antagonist, cromylin, an antibiotic, a sphingolipid, or a decongestant. | 2011-10-20 |
20110257116 | BIOSURFACTANT-CONTAINING SKIN CARE COSMETIC AND SKIN ROUGHNESS-IMPROVING AGENT - The present invention relates to a cosmetic for skin roughness improvement/skin care containing a biosurfactant, particularly MEL-A, MEL-B or MEL-C. | 2011-10-20 |
20110257117 | OLIVE COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS - A method of treating an inflammatory condition with a hydroxytyrosol-rich composition. Improvement is monitored as a reduction in the levels of a biochemical marker such as homocysteine or C-reactive protein. The composition may be administered in an amount and for a period sufficient to effect a drop in the level of the biochemical marker. | 2011-10-20 |
20110257118 | Vascular Circulation in Peripheral and/or Small Blood Vessels - The invention relates to compositions, and methods of use thereof, containing polyphenols such as flavanols, procyanidins, their derivatives and epimers thereof, for improving vascular circulation in peripheral and/or small blood vessels. | 2011-10-20 |
20110257119 | Microcirculation improvement and/or treatment - This invention relates to compositions, and methods of use thereof, for improving microcirculation in a diabetic subject, and for dietary management of diabetes-associated condition(s) comprising administering certain polyphenols such as flavanols, procyanidins, or pharmaceutically acceptable salts or derivatives thereof to the subject in need thereof. | 2011-10-20 |
20110257120 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B - This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: | 2011-10-20 |
20110257121 | PURINE NUCLEOSIDE PHOSPHORAMIDATE - Disclosed herein is a compound represented by formula 1 or its hydrate thereof in crystalline or crystal-like form. | 2011-10-20 |
20110257122 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: | 2011-10-20 |
20110257123 | ARYL/ALKYL VINYL SULFONE HYALURONIC ACID DERIVATIVES - A hyaluronic acid derivative, and methods of producing and using said derivative, the derivative comprising n repeating units and having the general structural formula (I), wherein, in at least one repeating unit, one or more of R1, R2, R3, R4 comprises an etherbound aryl/alkyl sulfone having the general structural fomula (II), wherein R comprises an alkyl- or aryl-group, and otherwise R1, R2, R3, R4 are hydroxyl groups, OH. | 2011-10-20 |
20110257124 | Esterified Polysaccharide Osmotics - The present invention relates to esterified polysaccharide osmotics, use of same, processes for synthesis of same as well as compositions containing same. | 2011-10-20 |
20110257125 | Mucomimetic compositions and uses therefore - The present invention relates to mucomimetic and ophthalmic solutions comprising a cationic multimeric antimicrobial agent such as polyaminopropyl biguanide and a magnesium, calcium or magnesium/calcium complex of an anionic polymer such as hyaluronate, alginate, carboxymethyl cellulose, chondroitin sulfate or mixtures thereof. In specific embodiments, the solutions include additional components such as a surfactant, a viscosity-modifying agent, a tonicity agent and a buffer. The solutions are biocompatible with and are highly comfortable when administered to mucous membranes, including those of the eye, as well as are effective disinfectants. | 2011-10-20 |
20110257126 | WATER SOLUBLE CURCUMIN COMPOSITIONS FOR USE IN ANTI-CANCER AND ANTI-INFLAMMATORY THERAPY - The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumour and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases. In a fifth aspect, the present invention relates to the use of a pharmaceutical composition comprising said water soluble curcumin derivatives in the treatment of cancer and inflammatory diseases and to a new pharmaceutical composition comprising said water soluble curcumin derivatives. | 2011-10-20 |
20110257127 | A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are novel compounds that are A | 2011-10-20 |
20110257128 | 2-Alkyl-Cycloalk(en)yl-Carboxamides - Novel 2-alkylcycloalk(en)ylcarboxamides of the formula (I) | 2011-10-20 |
20110257129 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS - 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds. | 2011-10-20 |
20110257130 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders - Compounds are provided which can be useful in reducing the activity of an angiotensin-converting enzyme and thus be used to treat or prevent a renin-angiotensin aldosterone system-related disorder. These compounds include lipoic acid derivatives such as prolyl lipoic acid and pipecolinyl lipoic acid, and other compounds, and these compounds are useful in treating hypertension, stroke, or other renin-angiotensin aldosterone system-related disorders in human or animal patients. Pharmaceutical compositions prepared using these compounds and methods of treatment using these compounds are also provided. | 2011-10-20 |
20110257131 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS - (Unsubstituted or substituted phenyl)-alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are disclosed. The compounds are able to inhibit excessive or inappropriate bone resorption. The compounds are of the formula I, | 2011-10-20 |
20110257132 | CHARGED PHOSPHOLIPID COMPOSITIONS AND METHODS FOR THEIR USE - The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins. | 2011-10-20 |
20110257133 | DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST - S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage. | 2011-10-20 |
20110257134 | CO-CRYSTALS OF TRAMADOL AND NSAIDs - The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs, processes for preparation of the same, their uses in pharmaceutical formulations, and for the treatment of various disorders, including pain. | 2011-10-20 |
20110257135 | TOPICAL PESTICIDE FORMULATION - Described are formulations and methods for animal pest control. A formulation for topical administration to animal pests includes a solution including an effective amount of cholecalciferol (also known as Vitamin D3) and at least one dermal penetrant or carrier, such that a lethal dose of the cholecalciferol can be delivered transdermally to an animal pest in solution, thereby being absorbed into the animal's bloodstream and subsequently causing the death of the animal. The formulation and method is effective at killing pests such as mice, rats, stoats, weasels, ferrets, rabbits, hedgehogs and possums. | 2011-10-20 |
20110257136 | Ophthalmic Formulations Of Cetirizine And Methods Of Use - The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis rhinitis, and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye. | 2011-10-20 |
20110257137 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as inhibitors of H | 2011-10-20 |
20110257138 | MONOTERPENES FOR TREATING RESPIRATORY TRACT DISEASES, IN PARTICULAR BRONCHOPULMONARY DISEASES - The invention relates to the combined use of at least one monoterpene which can be applied systemically, in particular perorally, and at least one respiratory tract therapeutic agent which can be applied topically, in particular through inhalation, for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or co-medication, of respiratory tract diseases, in particular bronchopulmonary diseases. Through the combined use of the systemic monoterpene with the topical, in particular inhaled respiratory tract therapeutic agent, the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly, in particular in a synergistic manner, on the one hand, and the required dosage thereof can be reduced significantly on the other hand, combined with the resulting advantages (e.g., avoidance or reduction of side effects). | 2011-10-20 |